Showing 251-260 of 5833 results for "".
In-person vs. Telehealth: Patient Preference and the Future of Engagement
https://practicaldermatology.com/topics/practice-management/in-person-vs-telehealth-patient-preference-and-the-future-of-engagement/23502/As Americans emerge from the pandemic, evidence suggests that patients may appreciate choices in how they interact with physicians.Are You Taking Advantage of Two Everyday Tax-Favored Assets?
https://practicaldermatology.com/topics/practice-management/are-you-taking-advantage-of-two-everyday-tax-favored-assets/23229/Are you taking advantage of two everyday tax-favored assets?Give Employee Feedback With Confidence
https://practicaldermatology.com/topics/practice-management/give-employee-feedback-with-confidence/20769/Ten tips to effectively communicate feedback to help employees grow and improve.FDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Up the Authenticity Factor on Your Dermatology Social Media
https://practicaldermatology.com/topics/practice-management/up-the-authenticity-factor-on-your-dermatology-social-media/23423/Strike the right tone and find the balance needed to truly engage with your current and potential patients.Buyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dABD Eyes Mohs Certification, Sun's Ilumya Approved, FUE Update
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abd-eyes-mohs-certification-sun-s-ilumya-approved-fue-update/18319/The American Board of Dermatology has notified the American Board of Medical Specialties it wants to offer a subspecialty certificate in Micrographic Dermatologic Surgery. Dermatologists react. Ilumya or tildrakizumab from Sun Pharma is approved for moderate to severe psoriasis. Medicine the MusicalDoctors Betrayed by Traditional Financial Strategies
https://practicaldermatology.com/topics/practice-management/doctors-betrayed-by-traditional-financial-strategies/20960/Part one of this two-part series explores why financial advice for the “average” consumer isn't always the best advice for dermatologists.